Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Buprenorphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : IntelGenx
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
Details : Belbuca-Generic (buprenorphine) is a partial mu-opioid receptor agonist and kappa-opioid antagonist for severe chronic pain; it received a CRL from the FDA for its ANDA.
Product Name : Belbuca-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 04, 2024
Lead Product(s) : Buprenorphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : IntelGenx
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla®
Details : Taytulla® is an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy. Annual market sales for Taytulla® for the twelve month period ending August, 2020 were $157 million, according to IQVIA™.
Product Name : Gemmily
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : Norethisterone Acetate,Ethinyl Estradiol,Ferrous Fumarate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable